Jeffery J. Anderson

The Behavioral Profile of the Potent and Selective mGlu5 Receptor Antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in Rodent Models of Anxiety

Chris S Busse, Jesse Brodkin, David Tattersall et al. · Neuropsychopharmacology · 2004 · 157 citations · Full text

Psychiatry, Behavioral Neuroscience, Medicine +11

In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine)

Jeffery J. Anderson, Margaret Bradbury, Darlene R. Giracello et al. · European Journal of Pharmacology · 2003 · 136 citations

Biochemistry, Functional Selectivity, Medicine +11

[3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine Binding to Metabotropic Glutamate Receptor Subtype 5 in Rodent Brain: In Vitro and in Vivo Characterization

Jeffery J. Anderson, Sara Rao, Blake A. Rowe et al. · Journal of Pharmacology and Experimental Therapeutics · 2002 · 107 citations · Full text

Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge

Daniel S. Lorrain, Hervé Schaffhauser, Una C. Campbell et al. · Neuropsychopharmacology · 2003 · 94 citations · Full text

Locomotor Responses, Neurophysiology, Medicine +11

Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897

Jeffery J. Anderson, Greg Holtz, Patricia Baskin et al. · Biochemical Pharmacology · 2005 · 93 citations

Molecular Pharmacology, Neurodegenerative Diseases, Alzheimer's Disease +8